CD40 Ligand Blockade for Prevention of Graft-Versus-Host Disease This scoping review was conducted based on the Arksey and O'Malley framework and the work of Levac et al. The databases searched ...

This study evaluated three LLMs (GPT-3.5-turbo-0125, GPT-4-turbo, and GPT-4o) using drug names from HemOnc ontology. The assessment included 367 generic-to-brand and 2,516 brand-to-generic pairs, ...

Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus–Initiated Oropharynx Cancer Despite ...

Research suggests that a substantial proportion of those diagnosed with cancer may experience portions of their diagnosis and treatment as traumatic. 6 Additionally, many individuals diagnosed with ...

In the article that accompanies this editorial, Babiker et al 12 present the data that tumor-treating fields (TTFs) combined with gemcitabine plus nab-paclitaxel improved median overall survival ...

Background: PV is characterized by red blood cell overproduction. Rusfertide is a subcutaneous (SC), self-injected, first-in-class peptide hepcidin mimetic that decreases erythrocytosis. VERIFY ...

Background: Multiple observational studies have reported that post-diagnosis physical activity (PA) is associated with reduced recurrence rates in early-stage colon cancer but epidemiologic data is ...

Older patients with classic Hodgkin lymphoma (cHL) have inferior survival compared with younger patients. We report a subset analysis of older patients (60 years and older) enrolled in the phase three ...

Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ...

In the article that accompanies this editorial, He et al 3 report the results of a randomized study that evaluated the role of osimertinib given in the preoperative (neoadjuvant) therapy setting ...

Background: Optimal timing of cytoreduction in non-frail patients (pts) with seemingly resectable stage IIIB-IVB ovarian, tubal, and peritoneal carcinoma (OC) remains controversial.Methods: TRUST is ...

Background: The phase 3 CheckMate 77T study demonstrated statistically significant and clinically meaningful improvement in EFS with perioperative NIVO vs PBO in pts with resectable NSCLC. pCR rates ...